{"id":"arct-021-dose-1","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site pain"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by encoding for a specific antigen, which is then produced by the host cells to stimulate an immune response.","oneSentence":"ARCT-021 is a mRNA-based vaccine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:06.746Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19"}]},"trialDetails":[{"nctId":"NCT05037097","phase":"PHASE1, PHASE2","title":"A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2021-08-30","conditions":"COVID-19, SARS-CoV-2 Infection, Corona Virus Infection","enrollment":72},{"nctId":"NCT04668339","phase":"PHASE2","title":"A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults","status":"TERMINATED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2021-01-07","conditions":"Covid19, SARS-CoV Infection, Corona Virus Infection","enrollment":581},{"nctId":"NCT04728347","phase":"PHASE2","title":"Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021","status":"TERMINATED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2021-01-04","conditions":"SARS-CoV-2","enrollment":65},{"nctId":"NCT04480957","phase":"PHASE1, PHASE2","title":"Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2020-08-04","conditions":"SARS-CoV-2","enrollment":106}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ARCT-021 Dose 1","genericName":"ARCT-021 Dose 1","companyName":"Arcturus Therapeutics, Inc.","companyId":"arcturus-therapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"ARCT-021 Dose 1 is an investigational vaccine being studied for its safety and tolerability in healthy adult subjects with SARS-CoV-2, COVID-19, SARS-CoV-2 Infection, Corona Virus Infection, and Covid19. The study, titled \"Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects,\" is a Phase 1/2 randomized, double-blinded, placebo-controlled, ascending dose study.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}